Apixaban for Stroke Prevention in Atrial Fibrillation: A Review of the Clinical Trial Evidence

2011 ◽  
Vol 39 (4) ◽  
pp. 7-16
Author(s):  
Scott W. Yates
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Trial ◽  
Stroke Prevention ◽  
Clinical Trial Evidence ◽  
Trial Evidence

Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real‐World vs . Clinical Trial Evidence

2021 ◽  
Author(s):  
Wern Yew Ding ◽  
José Miguel Rivera‐Caravaca ◽  
Francisco Marín ◽  
Guowei Li ◽  
Vanessa Roldán ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Trial ◽  
Real World ◽  
Number Needed To Treat ◽  
Clinical Trial Evidence ◽  
Trial Evidence

scholarly journals Sulfonylureas at the Glomerular Battlefield

2018 ◽  
Vol 14 (2) ◽  
pp. 15
Author(s):  
Sanjay Kalra ◽  
Deepak Khandelwal ◽  
Sarita Bajaj ◽  
Ashok Kumar Das
Keyword(s):  
Clinical Trial ◽  
Glucose Homeostasis ◽  
Diabetes Complications ◽  
Cardiovascular Health ◽  
Glucose Lowering ◽  
Meeting Point ◽  
Normal Glucose ◽  
Clinical Trial Evidence ◽  
Trial Evidence

The kidney is important in the context of diabetes not only because it is involved in normal glucose homeostasis, but also because it is one of the most important end organs to be involved in diabetes complications. Glomeruli are the meeting point of both microvascular, or renal; and macrovascular, or cardiovascular, health in diabetes. Sulfonylureas are effective glucose-lowering drugs. While a sulfonylurea-based glucose-lowering strategy is nephro-safe and nephro-protective, this aspect of sulfonylurea pharmaco-biology has not been highlighted earlier. In this editorial, we discuss current preclinical and clinical trial evidence regarding the performance of modern sulfonylureas at the glomerular battlefield.

Sign in / Sign up

Export Citation Format

Share Document